209 related articles for article (PubMed ID: 35717429)
1. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features.
Mori M; Palumbo D; Muffatti F; Partelli S; Mushtaq J; Andreasi V; Prato F; Ubeira MG; Palazzo G; Falconi M; Fiorino C; De Cobelli F
Eur Radiol; 2023 Jun; 33(6):4412-4421. PubMed ID: 36547673
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade.
Chiti G; Grazzini G; Flammia F; Matteuzzi B; Tortoli P; Bettarini S; Pasqualini E; Granata V; Busoni S; Messserini L; Pradella S; Massi D; Miele V
Radiol Med; 2022 Sep; 127(9):928-938. PubMed ID: 35917099
[TBL] [Abstract][Full Text] [Related]
4. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
[TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
6. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.
Gu D; Hu Y; Ding H; Wei J; Chen K; Liu H; Zeng M; Tian J
Eur Radiol; 2019 Dec; 29(12):6880-6890. PubMed ID: 31227882
[TBL] [Abstract][Full Text] [Related]
7. Combination of clinical, radiomic, and "delta" radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma.
Krishna S; Sertic A; Liu ZA; Liu Z; Darling GE; Yeung J; Wong R; Chen EX; Kalimuthu S; Allen MJ; Suzuki C; Panov E; Ma LX; Bach Y; Jang RW; Swallow CJ; Brar S; Elimova E; Veit-Haibach P
Front Oncol; 2023; 13():892393. PubMed ID: 37645426
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
9. Radiomic Cancer Hallmarks to Identify High-Risk Patients in Non-Metastatic Colon Cancer.
Caruso D; Polici M; Zerunian M; Del Gaudio A; Parri E; Giallorenzi MA; De Santis D; Tarantino G; Tarallo M; Dentice di Accadia FM; Iannicelli E; Garbarino GM; Canali G; Mercantini P; Fiori E; Laghi A
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884499
[TBL] [Abstract][Full Text] [Related]
10. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract][Full Text] [Related]
11. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy.
Peeken JC; Bernhofer M; Spraker MB; Pfeiffer D; Devecka M; Thamer A; Shouman MA; Ott A; Nüsslin F; Mayr NA; Rost B; Nyflot MJ; Combs SE
Radiother Oncol; 2019 Jun; 135():187-196. PubMed ID: 30961895
[TBL] [Abstract][Full Text] [Related]
12. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors.
Homps M; Soyer P; Coriat R; Dermine S; Pellat A; Fuks D; Marchese U; Terris B; Groussin L; Dohan A; Barat M
Eur J Endocrinol; 2023 Oct; 189(4):476-484. PubMed ID: 37787635
[TBL] [Abstract][Full Text] [Related]
13. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
14. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
15. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.
Xu X; Zhang HL; Liu QP; Sun SW; Zhang J; Zhu FP; Yang G; Yan X; Zhang YD; Liu XS
J Hepatol; 2019 Jun; 70(6):1133-1144. PubMed ID: 30876945
[TBL] [Abstract][Full Text] [Related]
16. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy.
Polk SL; Choi JW; McGettigan MJ; Rose T; Ahmed A; Kim J; Jiang K; Balagurunathan Y; Qi J; Farah PT; Rathi A; Permuth JB; Jeong D
World J Gastroenterol; 2020 Jun; 26(24):3458-3471. PubMed ID: 32655269
[TBL] [Abstract][Full Text] [Related]
17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
18. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.
Benslama N; Bollard J; Vercherat C; Massoma P; Roche C; Hervieu V; Peron J; Lombard-Bohas C; Scoazec JY; Walter T
Invest New Drugs; 2016 Oct; 34(5):654-62. PubMed ID: 27230034
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy.
Lin CH; Yan JL; Yap WK; Kang CJ; Chang YC; Tsai TY; Chang KP; Liao CT; Hsu CL; Chou WC; Wang HM; Huang PW; Fan KH; Huang BS; Tung-Chieh Chang J; Tu SJ; Lin CY
Radiother Oncol; 2023 Dec; 189():109938. PubMed ID: 37806562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
